Abstracts data are unavailable or insuffi cient, indirect comparison is increasingly used across therapy areas, refl ected by recent NICE guidance. To maximise quality of submissions, analyses must use validated methodology, manage heterogeneity appropriately and clearly justify decisions and usage of methods and comparators. Rationale for use of indirect comparisons is also required.
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A COMPARISON OF REASONS FOR RECOMMENDATION AND REJECTION ACROSS FOUR HEALTH TECHNOLOGY APPRAISAL SYSTEMS CATEGORISED BY DISEASE
Plested M, Karia R, Samuels ER Heron Evidence Development Ltd, Luton, UK OBJECTIVES: Reasons provided by the health technology appraisal (HTA) agencies for the guidance issued vary across the board. Following interest from a previous ISPOR presentation, we sought to further investigate the reasons for recommendation/rejection between NICE, SMC, CADTH, and PBAC with a specifi c focus on disease-specifi c reasons. METHODS: A previously developed database was updated with data from submissions appraised between 31 May and 31 December 2008 by NICE, SMC, CADTH, and PBAC, in England/Wales, Scotland, Canada, and Australia, respectively. Submissions with opposing decision outcomes were included and were categorised by disease based on the BNF (cardiovascular system, CNS, endocrine system, gastro-intestinal system, infections, malignant diseases and immunosuppression, musculoskeletal and joint diseases, nutrition and blood, obstetrics, gynaecology, and urinary tract disorders, respiratory system, and skin). Reasons for acceptance/ rejection were analysed across the disease categories. RESULTS: In total, 83 submissions were included for analysis. Across all HTAs, the most common rejection reasons for skin disease interventions included "not more effective than comparators" and "not cost-effective"; these reasons were demonstrated in 100% of the submissions for interventions relating to skin disorders. The most common rejection reasons in malignant diseases and immunosuppression included "not cost-effective" and "concerns over the economic model" (100% for both). The majority of the reasons for rejection were reported in 50% or less of the submissions per disease group. Of the recommended interventions, those for the treatment of skin disease were all "more effective than placebo and comparators" as well as having a lower cost. Interventions for infectious diseases and obstetrics, gynaecology, and urinary tract disorders demonstrated a wide range of reasons for rejection. CONCLUSIONS: Sub-group analysis categorised by disease provides further insight into the primary reasons for rejection and recommendation across HTA bodies. Analysing trends within these submissions highlights potential obstacles for new interventions within a specifi c disease area. analyzed. Appraisals were grouped into positive and negative recommendations. The clinical and non-clinical reasons for rejection of use were studied. The positive guidances were divided into recommendations with major, minor and without restrictions. RESULTS: Thirty-two HTA reports received negative recommendations; 26 on the grounds of clinical evidence and 6 because of non-clinical issues. Among 26 recommendations, insuffi cient clinical effectiveness data was the most frequently stated reason (18 cases). In other eight guidances, the argument of poor effi cacy or safety was raised. Among non-clinical aspects, unacceptable cost-effectiveness ratio was given four times. The unacceptable budget impact and risk of off-label use were mentioned each one only once. Twenty-seven HTA reports received positive recommendations, of which 18 for use with major restrictions, 7 with minor restrictions and 2 without additional restrictions. Among those 18 recommendations, several restrictions were imposed simultaneously. The most common was prescription restricted to specifi c subpopulations (15 cases), followed by the need for an improvement of cost-effectiveness (6 cases), use as second line (5 cases), use if intolerant to other treatment (3 cases), reimbursement within specifi c period (2 cases). Among recommendations with minor restrictions, lowering price was mentioned fi ve times and use by specialist twice. The appraisal of cost-effectiveness analysis was included more frequently in positive rather than negative quidances; 63% vs. 57%. The study revealed that an ICER was above WHO threshold, accepted by AHTAPoL, in 65% of positive recommendations. An ICER was below threshold in 44% of negative recommendations. CONCLUSIONS: The negative and positive HTA guidances with major restrictions prevailed in Poland. Clinical rather than pharmacoeconomic aspects were the most common reason for an appraisal recommendation.
PHP85 REVIEW OF HTA RECOMMENDATIONS FOR DRUG THERAPIES IN
PHP86 PUBLICATION TRENDS OF BUDGET IMPACT ANALYSES OVER THE PAST SIX YEARS
Pathak P, Kowal-Podmore S, Munakata J P P IMS Health, Falls Church, VA, USA OBJECTIVES: Budget impact analyses (BIAs), along with cost-effectiveness analyses, are an essential part of a comprehensive economic assessment of a new health technology and increasingly required by national regulatory agencies and managed care organizations. This study describes the characteristics and growth of BIAs published in the literature over the past 5-6 years. METHODS: An initial search was conducted using PubMed, a service of the U.S. National Library of Medicine. Approximately 800 citations were retrieved using key words of "budget impact" and "budget analysis" and limits of "English Language" and "published within the last 6 years". Additional articles were obtained through ancestral and related article searches. All relevant BIA articles were identifi ed through an initial title review and secondary abstract review and included in this study. (2008), showing a steady upward trend. The publishing journals had impact factors ranging from 1.985 to 5.888. Just over half of published studies (18/32) assessed budget impact of a health technology in the United States, while the remaining studies were performed in European countries, Canada and Brazil. Although the majority of published BIAs (22/32) examined budget impact of a specifi c drug, several studies assessed budget impact of various procedures e.g. surgical, endoscopic. Fourteen (44%) of the published BIAs were performed in conjunction with a cost-effectiveness analysis. CONCLUSIONS: Despite increased demand for and recent growth in number of published BIAs, the absolute number of BIA studies published in peer-reviewed journals remains limited. Future studies should examine whether the quality of published BIAs has improved over time and examine changes in practices following the recently published recommendations of the ISPOR Task Force on good research practices for BIAs.
PHP87 THE IMPACT OF THE SUBMISSION SEQUENCE -WHICH APPRAISING BODY TO SUBMIT TO FIRST?
Karia R, Plested M Heron Evidence Development Ltd, Luton, UK OBJECTIVES: The outcomes of health technology assessment (HTA) appraisals conducted by appraising bodies vary greatly and are infl uenced by a range of factors. The aim of this research was to determine whether the sequence of agencies in which HTAs are submitted has an impact on the guidance issued. METHODS: Data from submissions to NICE, SMC and CADTH between 1 November 2005 and 31 December 2008 were included. Only interventions appraised by at least two agencies were of interest. Extracted information included the name of the intervention, the guidance issued and the date of guidance. In addition, a correlation between the sequence of submission and guidance issued was assessed. RESULTS: A total of 46 interventions were submitted to at least two appraising bodies. In 76% of cases, the fi rst body to conduct appraisals was the SMC. In contrast, only 4% of the submissions were submitted to
